ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency

ProMIS Neurosciences (TSX:PMN) a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced further results of its previously announced and ongoing preclinical program for Alzheimer’s disease (AD). ProMIS is pleased to announce that its lead product candidate for AD, PMN310, compared to aducanumab (Biogen) showed significantly greater binding to the neurotoxic oligomer-enriched fraction of amyloid beta (Aβ) in brain extract from eight confirmed AD brains.
As quoted in the press release:

Williams continued, “We are pleased to announce further results supportive of a best in class profile for our lead AD program.  In comparison to aducanumab, humanized PMN310 showed significantly greater binding to brain material from AD patients containing toxic Aβ oligomers, the root cause of disease. Affinity maturation of PMN310 is ongoing and may result in an even greater advantage with PMN310; we look forward to sharing these results in the coming months.”

Click here to read the full press release.